Related Experiment Video
Updated: Jul 25, 2026

Murine Isolated Heart Model of Myocardial Stunning Associated with Cardioplegic Arrest
Published on: August 6, 2015
Pediatric myocardial protection: an overview
B S Allen1, M J Barth, M N Ilbawi
1Division of Cardiovascular Surgery, The Heart Institute for Children, Hope Children's Hospital, Oak Lawn, IL 60453, USA.
Insights
This study presents a new bypass and cardioplegic strategy to protect infant hearts during surgery, significantly improving outcomes for pediatric patients. The approach minimizes intraoperative injury, enhancing safety for vulnerable young hearts undergoing complex procedures.
Area of Science:
- Pediatric Cardiac Surgery
- Cardiovascular Research
- Medical Device Infrastructure
Background:
- Infant hearts are highly susceptible to surgical damage due to preoperative hypertrophy, cyanosis, and ischemia.
- Existing strategies for myocardial protection in pediatric patients require enhancement to mitigate risks.
- Understanding vulnerability factors like cyanosis and ischemia is crucial for developing effective interventions.
Purpose of the Study:
- To describe the experimental infrastructure and clinical application of a novel bypass and cardioplegic strategy.
- To evaluate the strategy's effectiveness in limiting intraoperative injury and improving postoperative outcomes in pediatric cardiac surgery.
- To present data on cardioplegic management principles applied in this technique.
Main Methods:
- Development of a comprehensive bypass and cardioplegic strategy incorporating normoxia/hyperoxia bypass starts, leukocyte filtration, and warm induction/reperfusion.
- Utilized multidose blood cardioplegia with modified substrate and electrolyte balance (reduced calcium, increased magnesium).
- Integrated approach to minimize ischemia, allowing it only when necessary during pediatric surgeries.
Main Results:
- Successful clinical application in 567 pediatric patients over 2 years at the Heart Institute for Children and University of Illinois hospital.
- Included 72 patients with hypoplastic left heart syndrome over 4 years, demonstrating the strategy's versatility.
- The strategy effectively limited intraoperative injury and improved postoperative outcomes.
Conclusions:
- The described comprehensive bypass and cardioplegic strategy provides enhanced myocardial protection for infant hearts.
- Application of these principles can significantly improve the safety and outcomes of pediatric cardiac surgeries.
- This integrated approach represents a significant advancement in managing vulnerable infant hearts during bypass.
Abstract:
This article describes the experimental infrastructure and subsequent successful clinical application of a comprehensive bypass and cardioplegic strategy that limits intraoperative injury and improves postoperative outcomes in pediatric patients. The infant heart is at high risk of damage from poor protection because of preoperative hypertrophy, cyanosis, and ischemia. The background factors of vulnerability to damage caused by cyanosis and ischemia are discussed, together with studies of the infrastructure of strategies to use normoxia versus hyperoxia as bypass starts, white blood cell filtration, warm induction and reperfusion with substrate enhancements, multidose blood cardioplegia, and an integrated approach to allow ischemia only when vision is needed in pediatric surgeries. Data on cardioplegic management, including reducing calcium, increasing magnesium, and reducing perfusion pressure are shown, as used during this technique. These principles were applied to a consecutive series of 567 patients at the Heart Institute for Children and University of Illinois hospital over a 2-year period. Included also were 72 patients with hypoplastic left heart over a 4-year period with this myocardial management strategy. Application of these concepts may improve the safety of protection in infant hearts.
More Related Videos
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Cardiopulmonary Resuscitation IV: Pharmacological Management
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

